Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial
- Citation:
- Oncologist vol 24 (11) 1497-1501
- Year:
- 2019
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Pharmas:
- Exelixis, Inc
- Grants:
- U10CA180821, U10CA180882, U10CA180791, U10CA180833, U10CA180850, U10CA180857, U10CA180867, P30 CA008748
- Corr. Author:
- Authors:
- Daniel J. George Colin Hessel Susan Halabi M. Dror Michaelson Olwen Hahn Meghara Walsh Joel Picus Eric J. Small Shaker Dakhil Darren R. Feldman Milan Mangeshkar Christian Scheffold Michael J. Morris Toni K. Choueiri
- Networks:
- CA136, KS055, LAPS-IL057, LAPS-MA036, LAPS-MO011, LAPS-NC010, LAPS-NY016
- Study
- Alliance-A031203
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: